SS-31

Clinical-reference elamipretide research provides the most structured dosing context for SS-31. The current FDA-approved Forzinity label uses 40 mg subcutaneously once daily for patients weighing at least 30 kg, with a reduced 20 mg once-daily reference in adults with severe renal impairment who are not on dialysis. Earlier clinical programs have also evaluated daily subcutaneous exposure around 40 mg in primary mitochondrial myopathy and Barth syndrome research, and pharmacokinetic data describe dose-proportional exposure across 2 mg to 80 mg following daily subcutaneous dosing. These figures should be understood as clinical-reference context for elamipretide, not as personal dosing instructions for research-use SS-31.

Researcher-reported exploratory SS-31 discussions often describe substantially lower non-clinical ranges, commonly around 1-5 mg per day or several times weekly, while more aggressive mitochondrial research discussions may reference higher milligram-range exposure closer to clinical elamipretide models. These ranges are anecdotal and not standardized. Protocol design depends on the study model, route, concentration, mitochondrial endpoint, renal-clearance considerations, tolerability markers, and whether the research is focused on cellular stress, exercise-fatigue models, tissue protection, or broader mitochondrial function.

For storage and handling, SS-31 should follow standard peptide-integrity practices. Store unopened lyophilized vials refrigerated when possible and protected from direct light, heat, and repeated temperature changes. Once reconstituted, keep refrigerated and avoid unnecessary warming, freezing, or repeated agitation. If mixing is needed after adding diluent, gently swirl the vial rather than shaking it. Aggressive shaking can create foaming and may reduce peptide integrity over time.